Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iambic Therapeutics, Inc.IAM · Entity 184417 | Director · Chief Executive Officer | October 14, 2026 | October 14, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iambic Therapeutics, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,278,556 |
Reported balance
Holding disclosure · report date 2026-10-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,278,556 F1: Of the reported shares, 4,071 were issued pursuant to an early exercise provision and which vest in full on March 1, 2027. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.47 · Expires 2034-08-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: An option to purchase 137,696 shares was granted on May 16, 2023 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The shares subject to the option vest in 48 equal monthly installments beginning on July 1, 2023. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.47 · Expires 2034-08-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The option is subject to certain performance metrics. Prior to the date on which the reporting person became subject to Section 16, 50% of the shares subject to the option vested. The remaining 50% vest upon the Issuer's submission to the FDA of an IND application relating to cyclin-dependent kinase, as determined by the administrator of the Issuer's 2020 Equity Incentive Plan in accordance with the terms of the award. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73 · Expires 2036-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026. |
| Performance Share UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F7: Each PSU represents a contingent right to receive one share of Issuer common stock. F5: The performance-based restricted stock units, or PSUs, vest upon the satisfaction of certain milestones and a liquidity event. The milestone requirement will be satisfied upon the earlier of (i) (a) the first dosing of a subject in a human clinical trial for the Issuer's product targeting HER2 ("HER2 Product"), together with prior data and information concerning such product, would be sufficient to support the filing of a Marketing Authorization Application in the U.S. or (b) a foreign clinical trial that is equivalent to clause (a), including any clinical trial indicated to be a Phase 3 trial, (ii) entering into a partnering transaction in which the Issuer grants to a non-affiliate third party exclusive rights to commercialize (or any co-commercialization rights in) a HER2 Product in the U.S. and/or European Union, or (iii) a change in control. The liquidity event was satisfied on October 14, 2026, the effective date of the Issuer's initial public offering of common stock. F6: The event deadline is March 3, 2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 4,071 were issued pursuant to an early exercise provision and which vest in full on March 1, 2027.
F2: An option to purchase 137,696 shares was granted on May 16, 2023 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The shares subject to the option vest in 48 equal monthly installments beginning on July 1, 2023.
F3: The option is subject to certain performance metrics. Prior to the date on which the reporting person became subject to Section 16, 50% of the shares subject to the option vested. The remaining 50% vest upon the Issuer's submission to the FDA of an IND application relating to cyclin-dependent kinase, as determined by the administrator of the Issuer's 2020 Equity Incentive Plan in accordance with the terms of the award.
F4: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.
F5: The performance-based restricted stock units, or PSUs, vest upon the satisfaction of certain milestones and a liquidity event. The milestone requirement will be satisfied upon the earlier of (i) (a) the first dosing of a subject in a human clinical trial for the Issuer's product targeting HER2 ("HER2 Product"), together with prior data and information concerning such product, would be sufficient to support the filing of a Marketing Authorization Application in the U.S. or (b) a foreign clinical trial that is equivalent to clause (a), including any clinical trial indicated to be a Phase 3 trial, (ii) entering into a partnering transaction in which the Issuer grants to a non-affiliate third party exclusive rights to commercialize (or any co-commercialization rights in) a HER2 Product in the U.S. and/or European Union, or (iii) a change in control. The liquidity event was satisfied on October 14, 2026, the effective date of the Issuer's initial public offering of common stock.
F6: The event deadline is March 3, 2033.
F7: Each PSU represents a contingent right to receive one share of Issuer common stock.
VERACYTE, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,100 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,272 · Balance 31,100 F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:55 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0002034921-26-000002 · wk-form4_1781556938.xml · nonDerivative · entry 1 Miller Thomas F. · CIK 0002034921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,100 F1 · kind: Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:09 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 9,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000093 · wk-form4_1750709365.xml · nonDerivative · entry 1 Miller Thomas F. · CIK 0002034921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,828 F1 · kind: Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 16,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000141 · wk-form4_1725481156.xml · nonDerivative · entry 1 Miller Thomas F. · CIK 0002034921 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,507 F1 · kind: Restricted stock units awarded on September 3, 2024 vest as to one-third (1/3) of the shares on each of the first, second and third annual anniversaries of the date of grant. F2 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.